INmune Net Income Applicable To Common Shares vs Total Operating Expenses Analysis

INMB Stock  USD 5.44  0.12  2.26%   
INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Net Income Applicable To Common Shares and its Total Operating Expenses accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

Net Income Applicable To Common Shares vs Total Operating Expenses

Net Income Applicable To Common Shares vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Net Income Applicable To Common Shares account and Total Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between INmune Bio's Net Income Applicable To Common Shares and Total Operating Expenses is -0.98. Overlapping area represents the amount of variation of Net Income Applicable To Common Shares that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Net Income Applicable To Common Shares and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Applicable To Common Shares of INmune Bio are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Net Income Applicable To Common Shares i.e., INmune Bio's Net Income Applicable To Common Shares and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.98
Relationship DirectionNegative 
Relationship StrengthSignificant

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 710.64, whereas Selling General Administrative is forecasted to decline to about 6.4 M.
 2010 2023 2024 (projected)
Interest Income77.7K69.9K62.2K
Net Interest Income77.7K69.9K62.2K

INmune Bio fundamental ratios Correlations

-0.080.60.990.92-0.780.720.980.980.870.880.980.310.92-0.970.90.930.850.00.950.720.440.970.95-0.25-0.86
-0.08-0.25-0.02-0.290.22-0.23-0.26-0.26-0.18-0.29-0.26-0.19-0.30.25-0.23-0.04-0.350.53-0.130.31-0.27-0.28-0.270.180.29
0.6-0.250.540.81-0.960.980.560.560.90.860.570.910.7-0.580.560.740.83-0.120.760.710.980.570.49-0.86-0.9
0.99-0.020.540.89-0.740.670.960.960.840.830.960.260.87-0.960.870.910.790.040.920.720.370.950.94-0.22-0.81
0.92-0.290.810.89-0.920.90.920.920.970.960.920.610.91-0.950.80.910.9-0.10.930.710.690.930.89-0.57-0.94
-0.780.22-0.96-0.74-0.92-0.99-0.74-0.74-0.98-0.94-0.75-0.8-0.820.76-0.71-0.89-0.910.05-0.9-0.79-0.9-0.75-0.680.740.97
0.72-0.230.980.670.9-0.990.690.690.960.930.690.860.79-0.710.650.830.88-0.110.850.760.930.70.62-0.81-0.94
0.98-0.260.560.960.92-0.740.691.00.830.881.00.280.94-0.990.890.880.86-0.080.920.590.40.990.98-0.22-0.84
0.98-0.260.560.960.92-0.740.691.00.830.881.00.280.94-0.990.890.880.86-0.080.920.590.40.990.98-0.22-0.84
0.87-0.180.90.840.97-0.980.960.830.830.960.840.720.87-0.860.780.930.91-0.030.940.810.810.840.79-0.67-0.97
0.88-0.290.860.830.96-0.940.930.880.880.960.890.630.96-0.880.860.870.96-0.140.920.670.770.890.85-0.59-0.98
0.98-0.260.570.960.92-0.750.691.01.00.840.890.270.95-0.980.920.880.87-0.090.920.590.410.990.98-0.21-0.85
0.31-0.190.910.260.61-0.80.860.280.280.720.630.270.41-0.330.180.520.58-0.10.510.620.940.280.2-0.95-0.66
0.92-0.30.70.870.91-0.820.790.940.940.870.960.950.41-0.910.920.850.95-0.150.910.570.580.950.92-0.34-0.92
-0.970.25-0.58-0.96-0.950.76-0.71-0.99-0.99-0.86-0.88-0.98-0.33-0.91-0.86-0.87-0.830.07-0.9-0.6-0.43-0.99-0.980.30.84
0.9-0.230.560.870.8-0.710.650.890.890.780.860.920.180.92-0.860.790.85-0.110.850.490.430.920.9-0.16-0.85
0.93-0.040.740.910.91-0.890.830.880.880.930.870.880.520.85-0.870.790.890.050.990.880.620.850.8-0.39-0.9
0.85-0.350.830.790.9-0.910.880.860.860.910.960.870.580.95-0.830.850.89-0.250.930.670.740.850.79-0.47-0.96
0.00.53-0.120.04-0.10.05-0.11-0.08-0.08-0.03-0.14-0.09-0.1-0.150.07-0.110.05-0.25-0.010.17-0.14-0.1-0.090.10.1
0.95-0.130.760.920.93-0.90.850.920.920.940.920.920.510.91-0.90.850.990.93-0.010.820.640.90.85-0.4-0.94
0.720.310.710.720.71-0.790.760.590.590.810.670.590.620.57-0.60.490.880.670.170.820.620.550.49-0.49-0.72
0.44-0.270.980.370.69-0.90.930.40.40.810.770.410.940.58-0.430.430.620.74-0.140.640.620.420.33-0.89-0.81
0.97-0.280.570.950.93-0.750.70.990.990.840.890.990.280.95-0.990.920.850.85-0.10.90.550.420.99-0.26-0.85
0.95-0.270.490.940.89-0.680.620.980.980.790.850.980.20.92-0.980.90.80.79-0.090.850.490.330.99-0.19-0.79
-0.250.18-0.86-0.22-0.570.74-0.81-0.22-0.22-0.67-0.59-0.21-0.95-0.340.3-0.16-0.39-0.470.1-0.4-0.49-0.89-0.26-0.190.6
-0.860.29-0.9-0.81-0.940.97-0.94-0.84-0.84-0.97-0.98-0.85-0.66-0.920.84-0.85-0.9-0.960.1-0.94-0.72-0.81-0.85-0.790.6
Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

INmune Bio fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets24.5M40.7M99.9M81.8M57.0M41.6M
Total Current Liabilities700.4K1.8M4.4M10.9M18.5M19.4M
Total Stockholder Equity23.6M38.8M80.2M60.1M38.1M33.6M
Net Tangible Assets7.1M22.2M63.7M43.6M50.1M52.6M
Retained Earnings(21.3M)(33.4M)(63.7M)(91.0M)(121.0M)(115.0M)
Accounts Payable692.1K1.5M3.8M5.2M7.9M8.3M
Cash7.0M22.0M74.8M52.2M35.8M23.6M
Cash And Short Term Investments7.0M22.0M74.8M52.2M35.8M23.6M
Capital Surpluse44.8M72.1M143.9M151.8M174.6M183.3M
Total Liab860.5K1.9M19.7M21.7M18.9M19.8M
Total Current Assets7.8M24.0M82.6M64.7M39.9M27.2M
Common Stock8.7K10.8K13.5K18K817K857.9K
Net Debt(6.8M)(21.8M)(59.6M)(36.8M)(25.4M)(26.7M)
Non Current Assets Total16.7M16.7M17.3M17.1M17.1M16.2M
Net Receivables645.4K1.8M5.5M8.5M2.4M2.8M
Common Stock Total Equity8.7K10.8K13.5K18K20.7K12.9K
Common Stock Shares Outstanding10.3M12.0M16.1M17.9M18.0M14.8M
Liabilities And Stockholders Equity24.5M40.7M99.9M81.8M57.0M46.8M
Non Current Liabilities Total160.2K126.3K15.4M10.8M397K377.2K
Other Current Assets769.3M220K2.3M4.1M1.7M1.6M
Other Stockholder Equity44.9M72.1M143.9M151.8M159.1M85.4M
Accumulated Other Comprehensive Income(8.5K)10.7K1K(699K)(799K)(759.1K)
Net Invested Capital23.6M38.8M94.7M74.8M48.1M49.4M
Net Working Capital7.1M22.2M78.2M53.8M21.5M29.0M
Retained Earnings Total Equity(21.3M)(33.4M)(63.7M)(91.0M)(81.9M)(77.8M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.45)
Return On Equity
(0.99)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.